Announcement PDF ASX Announcement 18/06/2021 Investor Webinar Presentation Today Emyria Limited (ASX: EMD) (Emyria or the Company), a drug development and clinical services company, is pleased to announce its participation in the ShareCafe Small Cap "Hidden Gems"Webinar, to be held today (Friday 18th of June 2021) from 12:30pm AEST / 10:30am AWST. Managing Director, Dr Michael Winlo will provide an overview of the Company’s data-backed drug registration programs (EMD-003, EMD-004 and EMDMA-001) and recent data validation accomplishments with IQVIA (NYSE: IQV). This webinar is able to be viewed live via Zoom and will provide viewers the opportunity to hear from, and engage with, a range of ASX-listed leading micro/mid cap companies. To access further details of the event and to register at no cost, please copy and paste the following link into your internet browser: https://us02web.zoom.us/webinar/register/4316203521321/WN_I70J9LKPQAOnMW5Hc0aeOQ A recorded copy of the webinar will be made available following the event. A copy of the investor presentation to be delivered during the webinar is attached. This announcement has been approved and authorised by the Board of Emyria Limited. For further information on Emyria: Dr Michael Winlo Managing Director (08) 6559 2800 mwinlo@emyria.com Lexi O’Halloran Investor Relations + 61 (0) 404 577 076 lexi@janemorganmanagement.com.au Andrew Williams Media Relations +61 (0) 412 614 125 andreww@profilemedia.com.au 1 About Emyria (www.emyria.com) Emyria Limited is a data-backed, drug development company. Emyria’s Treatments target unmet needs and are focused on obtaining approval from major global regulators. Emyria’s drug development programs are informed by insights generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria’s independent clinical services (Emerald Clinics - www.emeraldclinics.com.au) Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs. Emyria’s first drug development program, EMD-003 is targeting unmet needs in mental health. Specifically psychological distress and the symptoms of anxiety, depression and stress. Emyria’s second drug development program, EMD-004 is targeting symptoms related to Irritable Bowel Syndrome (IBS). Emyria is also leading the development of psychedelic-assisted therapy program with the the launch of EMDMA-001, an MDMA-assisted psychotherapy program for patients with Post-Traumatic Stress Disorder (PTSD). Cautionary Note on Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. 2